Arikayce

Report
11 Pages
September 2018
Region: Global
Citeline
ID: 4775283

Drug Overview
Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM.

These infections can present in a variety of patients, including those with cystic fibrosis, although Insmed is excluding these patients from its trials.

Insmed has also conducted trials of Arikayce for the specific treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients. However, this indication has been deprioritized in favor of further developing the drug for the NTM market opportunity.

CONTENTS

OVERVIEW

Drug Overview
Product Profiles
Arikayce : Cystic fibrosis

LIST OF FIGURES

Figure 1: Arikayce for cystic fibrosis – SWOT analysis
Figure 2: The authors drug assessment summary of Arikayce for cystic fibrosis
Figure 3: The authors drug assessment summary of Arikayce for cystic fibrosis

LIST OF TABLES

Table 1: Arikayce drug profile
Table 2: Arikayce Phase III data in cystic fibrosis

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9668EUR$10,000USD£8,304GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47373EUR$49,000USD£40,691GBP

Table of Contents

Related Topics

Related Reports

Non-cystic fibrosis bronchiectasis - Pipeline Insight, 2024

Cystic Fibrosis - Pipeline Insight, 2024

Global Cystic Fibrosis Treatment Market Report and Forecast 2023-2031

Cystic Fibrosis Market - Forecasts from 2024 to 2029

Global Cystic Fibrosis Lung Disease Market: Analysis By Drug Type, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast